Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cholesterol
Biotech
Lilly preps gene editor for ph. 2 after strong cholesterol cuts
A one-time infusion of a Verve base editor led to a sustained 62% drop in cholesterol, clearing the bar set by approved PCSK9 inhibitors.
Darren Incorvaia
May 25, 2026 8:45am
Merck dives into data showing PCSK9 pill easily outswims rivals
Mar 30, 2026 11:45am
Daiichi pens pact for high cholesterol digital therapeutic
Mar 5, 2026 9:20am
Scribe eyes clinic as CRISPR candidates lower lipids in animals
Nov 17, 2025 9:22am
CRISPR Tx sees 80% fall in LDL, triglycerides after in vivo edit
May 7, 2025 10:00am
Marea rises toward phase 2b after posting cholesterol data
May 7, 2025 8:25am
